NUVB Covered Call Strategy
NUVB (Nuvation Bio Inc.), in the Healthcare sector, (Biotechnology industry), listed on NYSE.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
NUVB (Nuvation Bio Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.66B, a beta of 1.52 versus the broader market, a 52-week range of 1.57-9.75, average daily share volume of 4.4M, a public-listing history dating back to 2020, approximately 273 full-time employees. These structural characteristics shape how NUVB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.52 indicates NUVB has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a covered call on NUVB?
A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.
Current NUVB snapshot
As of May 15, 2026, spot at $4.34, ATM IV 147.80%, IV rank 46.81%, expected move 31.24%. The covered call on NUVB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this covered call structure on NUVB specifically: NUVB IV at 147.80% is mid-range versus its 1-year history, so the credit collected on a NUVB covered call sits in line with its long-run distribution, with a market-implied 1-standard-deviation move of approximately 31.24% (roughly $1.36 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NUVB expiries trade a higher absolute premium for lower per-day decay. Position sizing on NUVB should anchor to the underlying notional of $4.34 per share and to the trader's directional view on NUVB stock.
NUVB covered call setup
The NUVB covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NUVB near $4.34, the first option leg uses a $4.56 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NUVB chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NUVB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $4.34 | long |
| Sell 1 | Call | $4.56 | N/A |
NUVB covered call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.
NUVB covered call payoff curve
Modeled P&L at expiration across a range of underlying prices for the covered call on NUVB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use covered call on NUVB
Covered calls on NUVB are an income strategy run on existing NUVB stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
NUVB thesis for this covered call
The market-implied 1-standard-deviation range for NUVB extends from approximately $2.98 on the downside to $5.70 on the upside. A NUVB covered call collects premium on an existing long NUVB position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether NUVB will breach that level within the expiration window. Current NUVB IV rank near 46.81% is mid-range against its 1-year distribution, so the IV signal is neutral; the covered call thesis on NUVB should anchor more to the directional view and the expected-move geometry. As a Healthcare name, NUVB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NUVB-specific events.
NUVB covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NUVB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NUVB alongside the broader basket even when NUVB-specific fundamentals are unchanged. Short-premium structures like a covered call on NUVB carry tail risk when realized volatility exceeds the implied move; review historical NUVB earnings reactions and macro stress periods before sizing. Always rebuild the position from current NUVB chain quotes before placing a trade.
Frequently asked questions
- What is a covered call on NUVB?
- A covered call on NUVB is the covered call strategy applied to NUVB (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With NUVB stock trading near $4.34, the strikes shown on this page are snapped to the nearest listed NUVB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are NUVB covered call max profit and max loss calculated?
- Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the NUVB covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 147.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a NUVB covered call?
- The breakeven for the NUVB covered call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NUVB market-implied 1-standard-deviation expected move is approximately 31.24%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a covered call on NUVB?
- Covered calls on NUVB are an income strategy run on existing NUVB stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
- How does current NUVB implied volatility affect this covered call?
- NUVB ATM IV is at 147.80% with IV rank near 46.81%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.